Docetaxel First May Boost Survival in mCRPC

]]>(MedPage Today) -- WASHINGTON--Sequencing docetaxel prior to second-generation androgen-blocking therapies may improve survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC), a retrospective study suggested...